Human VEGFR2/KDR/Flk-1 Antibody, R&D Systems™

VEGFR2/KDR/Flk-1

Polyclonal

Unconjugated

AAC16450

KDR

Mouse myeloma cell line NS0-derived recombinant human VEGFR2/KDR/Flk-1, Ala20-Glu764, Accession # AAC16450

100 μg

Primary

Detects human VEGFR2/KDR/Flk-1 in direct ELISAs and Western blots. In direct ELISAs, approximately 40% cross-reactivity with recombinant mouse VEGFR2 is observed and less than 10% cross-reactivity with recombinant human (rh) VEGFR1 and rhVEGFR3 is observed.

Human

IgG

Western Blot, Immunohistochemistry, Neutralization

LYOPH

Western Blot 1 ug/mL, Immunohistochemistry 5-15 ug/mL, Neutralization 0.05-0.25 ug/mL

CD309, CD309 antigen, EC 2.7.10, EC 2.7.10.1, Fetal liver kinase 1, fetal liver kinase-1, Flk1, Flk-1, FLK1tyrosine kinase growth factor receptor, KDR, Kinase insert domain receptor, kinase insert domain receptor (a type III receptor tyrosine kinase), KRD1, Ly73, Protein-tyrosine kinase receptor flk-1, soluble VEGFR2, vascular endothelial growth factor receptor 2, VEGF R2, VEGFR, VEGFR2, VEGFR-2

Goat

Affinity Purified

RUO

3791

Reconstitute at 0.2 mg/mL in sterile PBS.

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution.